ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. McCollum on Treatment in the First-Line Setting for CRC

A. David McCollum, MD
Published: Thursday, Nov 16, 2017



A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

According to McCollum, there was a burst of activity in the early part of this millennia with the approval of many agents. It was discovered that there were some molecular predictors to optimize regimens for particular forms of CRC.

RAS, BRAF, and HER2 testing might specify certain regimens for patients. Additionally, the sidedness of the tumor may predict which treatment will be successful, explains McCollum.
 


A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

According to McCollum, there was a burst of activity in the early part of this millennia with the approval of many agents. It was discovered that there were some molecular predictors to optimize regimens for particular forms of CRC.

RAS, BRAF, and HER2 testing might specify certain regimens for patients. Additionally, the sidedness of the tumor may predict which treatment will be successful, explains McCollum.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x